<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"AKT":1,
"Apocrine cancer":1,
"Breast":2,
"Multiplex PCR":1,
"Mutation":6,
"PIK3CA":1,
"Papilloma":1,
"Angioinvasion":1,
"Atypical follicular adenoma":1,
"CD61":1,
"Fibrin":1,
"Follicular thyroid carcinoma":2,
"Platelets":1,
"Thrombi":1,
"Vascular invasion":1,
"MicroRNA":3,
"Poorly differentiated thyroid carcinoma":1,
"Prognosis":9,
"Thyroid neoplasm":2,
"Tyrosine kinase inhibitor":3,
"Acinic cell carcinoma":2,
"Cushing syndrome":2,
"Ectopic ACTH":1,
"High-grade transformation":1,
"Parotid":1,
"Salivary gland":1,
"Laryngeal cancer":1,
"head and neck cancer":3,
"laryngectomy":1,
"Thyroid":18,
"biomarker":3,
"children":2,
"monitor":1,
"paresis":1,
"pediatric":4,
"recurrent laryngeal nerve":1,
"surgery":7,
"thyroidectomy":6,
"vocal cord paralysis":1,
"Parathyroid carcinoma":1,
"Pathological fracture":1,
"Primary hyperparathyroidism":2,
"CRLM":1,
"FDG-PET":1,
"GLUT1":1,
"HIF-1α":1,
"PKM2":1,
"Differentiated thyroid carcinoma":5,
"I-131 treatment":1,
"Recurrence rate":1,
"immune system":1,
"lymphocyte":1,
"monocytes":1,
"sorafenib":1,
"Hypothyroidism":2,
"TSH":1,
"Target therapy":1,
"Tyrosine kinase inhibitors":1,
"C-peptide":1,
"diabetes mellitus":1,
"gastric cancer":2,
"insulinoma-associated antigen-2 autoantibody":1,
"nivolumab":4,
"thyroid peroxidase autoantibody":1,
"177Lu-DOTATATE":1,
"68Ga-DOTATATE PET-CT":1,
"calcitonin doubling time":1,
"medullary thyroid carcinoma":4,
"peptide receptor radionuclide therapy":1,
"progression-free survival and overall survival":1,
"Agent Orange":1,
"Head and neck neoplasms":2,
"Mouth neoplasms":1,
"Nose neoplasms":1,
"Salivary gland neoplasms":2,
"Survival analysis":1,
"Thyroid neoplasms":10,
"Larynx":1,
"Osteosarcoma":1,
"Sarcomatoid carcinoma":1,
"Sarcomatous transformation":1,
"Spindle cell carcinoma":1,
"Squamous cell carcinoma":2,
"HER2":1,
"advanced gastric cancer":1,
"chemotherapy":2,
"trastuzumab":1,
"Lung adenocarcinoma":1,
"Multiple tumors":1,
"Next Generation Sequencing":1,
"Active surveillance":1,
"age":1,
"growth activity":1,
"papillary microcarcinoma":2,
"thyroid carcinoma":10,
"Endemic":1,
"Goiter":1,
"Iconography":1,
"Differentiated thyroid cancer":5,
"Pediatrics":1,
"Thyroid nodules":4,
"Endoscopic":1,
"Thyroid cancer":23,
"Transoral":1,
"Cancer research":1,
"Endocrinology":1,
"Hashimoto's thyroiditis":1,
"Immunology":1,
"Pathology":3,
"Tumor immune microenvironment":1,
"immunohistochemistry":6,
"malignant struma ovarii":1,
"papillary thyroid cancer":6,
"teratoma":1,
"hepatocellular carcinoma":1,
"living donor liver transplantation":1,
"malignancy":3,
"recurrence":7,
"surveillance":1,
"BRCAness":1,
"Breast cancer":7,
"Neoadjuvant chemotherapy":1,
"Triple negative":1,
"Conversion surgery":1,
"Liver metastasis":1,
"Deep learning":1,
"Lymphatic metastasis":2,
"Tomography, X-ray computed":1,
"bone metastases":1,
"embolization":1,
"long bones":1,
"pathological fractures":1,
"surgical treatment":1,
"Gamma-probe technique":1,
"Lymphoscintigraphy":1,
"Meta-analysis":1,
"Sentinel lymph node biopsy":1,
"ARAP1-AS1":1,
"HDAC2":1,
"PLIN1":1,
"miR-2110":1,
"AGEC":1,
"Afirma":1,
"Hashimoto":1,
"indeterminate nodule":1,
"Neuroendocrine tumor":1,
"SSTR":1,
"Somatostatin receptor":1,
"Struma ovarii":1,
"Strumal carcinoid":1,
"Cancer registration":1,
"China":1,
"Guidelines":2,
"Incidence":2,
"Cytotoxic T cells":1,
"Immune checkpoint":1,
"Lymphocytic infiltrate":1,
"Tissue microarray":3,
"intraparotid node":1,
"intraparotid node metastasis":1,
"mucoepidermoid cancer":1,
"parotid cancer":1,
"salivary gland tumour":1,
"NIFTP":1,
"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features":1,
"Thyroid nodule":5,
"Apoptosis":3,
"Lysine specific demethylase 5B":1,
"MicroRNA-448":1,
"Proliferation":3,
"Transforming growth factor β-induced factor 1":1,
"Diagnostic accuracy":1,
"palpation and ultrasound-guided FNAC":1,
"thyroid surgery":2,
"Adjuvant therapy":1,
"Follow-up":1,
"Poorly differentiated thyroid cancer":1,
"Radioactive iodine treatment":1,
"Treatment outcomes":1,
"Bilateral papillary thyroid cancer":1,
"Lobectomy":1,
"Multifocal":1,
"Occult disease":1,
"TI-RADS":1,
"Total thyroidectomy":3,
"Unifocal":1,
"circulating tumor DNA":1,
"distant metastasis":1,
"nomogram":2,
"papillary thyroid carcinoma":20,
"GATA-3":1,
"PitNET":1,
"Pituitary adenoma":1,
"Pituitary neuroendocrine tumour":1,
"Transcription factors":1,
"Gene Expression Omnibus":1,
"The Cancer Genome Atlas":1,
"PTEN":1,
"cancer predisposition":1,
"overgrowth":1,
"vascular anomaly":1,
"vascular malformation":1,
"oncogene testing":1,
"pediatric thyroid cancer":2,
"microwave ablation":2,
"thermal ablation":1,
"ultrasound":4,
"Central neck metastasis":1,
"Prophylactic central neck dissection":1,
"cN0 PTC":1,
"Calcium":1,
"Quality of life":1,
"Vitamin D":1,
"Lymph nodes":3,
"Mortality":2,
"Neoplasm staging":1,
"robotic thyroidectomy":1,
"transoral robotic thyroidectomy":1,
"transoral thyroidectomy":1,
"Chronic kidney disease":1,
"Immunosuppression":2,
"Kidney transplantation":1,
"Otorhinolaryngological dysfunctions":1,
"ATA risk stratification":1,
"TNM staging":1,
"response to therapy":1,
"Borderline tumor":1,
"Capsular invasion":1,
"Follicular neoplasm":1,
"Observer variation":1,
"99mTc - pertechnetate":1,
"radioiodine remnant ablation":1,
"salivary gland dynamic scintigraphy":1,
"xerostomia":1,
"CDC73 gene":1,
"Hypercalcemia":1,
"Hyperparathyroidism":1,
"Parathyroid cancer":1,
"Treatment":2,
"beta-catenin":1,
"desmoid-type fibromatosis":1,
"anaplastic carcinoma":1,
"papillary carcinoma":1,
"review":2,
"squamous carcinoma":1,
"childhood":1,
"radioactive iodine":1,
"activator of thyroid and retinoid receptor":1,
"aerobic glycolysis":1,
"hepatocarcinoma":1,
"sorafenib resistance":1,
"thyroid isthmus":1,
"thyroid isthmusectomy":1,
"thyroid lobectomy":1,
"EBRT":1,
"RAI":1,
"distant metastases":1,
"pulmonary metastases":1,
"esophageal cancer":1,
"patient-derived organoids":1,
"personalized medicine":1,
"TCGA":2,
"methylation-driven genes":1,
"prognostic indicators":1,
"Head and neck":2,
"Negative pressure dressings":1,
"Negative pressure wound therapy":1,
"Otolaryngology":1,
"Vacuum-assisted wound closure":1,
"Annexin A2":1,
"Dual-luciferase reporter assay":1,
"Microarray":2,
"RNA-sequencing":2,
"TOB1":1,
"Triple negative breast cancer":1,
"WEE2-AS1":1,
"miR-32-5p":1,
"Carcinoma":3,
"Inflammation":1,
"Oncology":2,
"Axillary imaging":1,
"Axillary lymph node biopsy":1,
"Axillary nodal burden":1,
"C-myc":1,
"HOTTIP":1,
"miR-744–5p":1,
"Endocrine disruptors chemicals":1,
"Environment":1,
"Pollutants":1,
"Thyroid diseases":1,
"Egypt":1,
"Endemic goiter":1,
"Hashimoto’s thyroiditis":3,
"RET":1,
"multiple endocrine neoplasia type 2A":1,
"pheochromocytoma":1,
"Adjuvant immunotherapy":1,
"Endocrine toxicity":1,
"Fertility":2,
"Late effects":1,
"Melanoma":1,
"ASH1-like histone lysine methyltransferase (ASH1L)":1,
"CCAT1":1,
"anaplastic thyroid cancer":1,
"cancer":2,
"epigenetics":2,
"gene expression":1,
"histone methylation":1,
"long noncoding RNA (lncRNA)":1,
"miR-200b-3p":1,
"microRNA (miRNA)":1,
"Anaplastic thyroid carcinoma":1,
"BRAF":2,
"Chemo-immunotherapy":1,
"Molecular testing":1,
"PD1 inhibitors":1,
"Disseminated granuloma annulare":1,
"Generalized granuloma annulare":1,
"Granuloma annulare":1,
"Granulomatous skin disease":1,
"PD-1 inhibitors":1,
"anasarca":1,
"immunocheck point inhibitors":1,
"immunotherapy":1,
"irAE":1,
"metastatic RCC":1,
"rhabdomyolysis":1,
"transaminitis":1,
"Central lymph node":1,
"multivariate analysis":1,
"papillary thyroid carcinoma (PTC)":1,
"prediction":1,
"risk model":1,
"Cervical":1,
"Ectopic thyroid tissue":1,
"Fibrosing":1,
"Fine needle aspiration cytology":2,
"Neck":2,
"IDH2 and PIK3CA mutation":1,
"Next-generation sequencing":2,
"Tall cell carcinoma with reversed polarity":1,
"diode":1,
"laser":1,
"metastatic":1,
"trachea":1,
"curative":1,
"palliative setting":1,
"stereotactic radiotherapy":1,
"American Thyroid Association":1,
"K-TIRADS":1,
"Korean Thyroid Imaging Reporting and Data System":1,
"nodule size":1,
"GLP-1R-imaging":1,
"Minigastrin":1,
"Neuroendocrine neoplasms":1,
"Somatostatin receptors":1,
"adverse drug reaction":1,
"drug safety":1,
"immune checkpoint inhibitors":2,
"pharmacovigilance":1,
"COVID-19":1,
"Endocrine emergencies":1,
"Endocrine surgery":1,
"dog":1,
"cancer panel":1,
"liquid-based cytology":1,
"anterior commissure involvement":1,
"early glottic cancer":1,
"independent prognostic factor":1,
"Buccal squamous cell carcinoma":1,
"Early-stage oral squamous cell carcinoma":1,
"Elective neck dissection":1,
"Occult lymph node metastasis":1,
"Drug resistance":1,
"Rechallenge":1,
"Resensitization":1,
"Fibroblast growth factor receptor":1,
"Head and neck squamous cell carcinoma":1,
"Predictive biomarker":1,
"Gene fusion":1,
"epidemiology":2,
"single centre study":1,
"2020":1,
"Adult":1,
"CT scan":1,
"Calcitonin":1,
"Carcinoembryonic antigen":1,
"Dysphagia":2,
"Female":1,
"Fine needle aspiration biopsy":1,
"Haematoxylin and eosin staining":1,
"Histopathology":2,
"Immunostaining":1,
"June":1,
"Kidney":1,
"Laparoscopy":1,
"Lymph node dissection":1,
"Medullary thyroid cancer":1,
"Neck pain/discomfort":1,
"Nephrectomy*":1,
"Papanicolaou staining*":1,
"Radioiodine":1,
"Radionuclide therapy":1,
"Renal cell carcinoma*":1,
"Synaptophysin":1,
"Thyroglobulin":1,
"Thyroid ultrasonography":1,
"Unique/unexpected symptoms or presentations of a disease":1,
"United States":1,
"Urology":1,
"White":1,
"Whole body scintigraphy*":1,
"Grave´s disease":1,
"Non-celiac wheat sensitivity":1,
"celiac disease":1,
"gut microbiota":1,
"iodine":2,
"iron":1,
"probiotics":1,
"Biological agents":1,
"cancer therapy":1,
"checkpoint inhibitors":1,
"ipilimumab":1,
"osimertinib":1,
"uveitis":1,
"vemurafenib":1,
"LIPH":1,
"PTC":1,
"circ_LDLR":1,
"miR-195-5p":1,
"Aspiration Biopsies, Fine Needle":1,
"Core Needle Biopsy":1,
"TERT":1,
"gene expression profile":1,
"Diagnosis":1,
"Differential":1,
"Mammary analogue&nbsp":1,
"secretory&nbsp":1,
"Mucoepidermoid":1,
"Cancer surgery":1,
"Dental surgery":1,
"Recurrent oral squamous cell carcinoma":1,
"Rehabilitation":1,
"Second free flap reconstruction":1,
"CHEK2":1,
"MEN":1,
"hypertension":1,
"multiple endocrine glands tumors":1,
"Cryptococcus neoformans":1,
"Sarcoidosis":1,
"Carcinoma, papillary":1,
"Surgical procedures, operative":2,
"Thyroid gland":1,
"CD56":1,
"Hashimoto′s thyroiditis":1,
"Ductal carcinoma in situ":1,
"Intraductal therapy":1,
"Minimally invasive":1,
"Nanomedicine":1,
"Personalized therapy":1,
"fractal dimension (FD)":1,
"gray-level co-occurrence matrix (GLCM) parameters":1,
"medical image analysis":1,
"nucleus chromatin architecture":1,
"thyroid carcinomas":1,
"BRAF V600E mutation":1,
"BRAF-activated long non-coding RNA":1,
"miR-9":1,
"Hürthle cell":1,
"metabolism":1,
"mitochondria":1,
"oncogenes":1,
"oxidative phosphorylation":1,
"endocrine cancer":2,
"thyroid disease":1,
"GC-MS":1,
"metabolomics":1,
"multinodular goiter":1,
"Adiponectin":1,
"Progranulins":1,
"Obesity":1,
"Thyroid cancer, papillary":1,
"anhydrous ethanol":1,
"radiofrequency ablation":2,
"Calea pinnatifida":1,
"sesquiterpene lactones":1,
"vibrational circular dichroism (VCD)":1,
"α,β-unsaturated carbonyl systems":1,
"Differential diagnosis":1,
"FTC variants":1,
"Molecular pathology":1,
"PTC variants":1,
"Rare tumors":1,
"Renal cell carcinoma":1,
"Thyroid metastasis":1,
"A-kinase interacting protein 1":1,
"clinicopathological features":1,
"disease-free survival":2,
"overall survival":2,
"genetic variation":1,
"lncRNA":1,
"thyroid function":1,
"Aggressiveness":1,
"Angiogenesis":2,
"Integrin (αvβ3)":1,
"SPECT/CT":1,
"DICER1":1,
"MET":1,
"Macrofollicular variant":1,
"Mediastinal tumour":1,
"carcinosarcoma":1,
"dissection":1,
"metastases":1,
"metastasis":3,
"pattern":1,
"predictor":1,
"KCKNs":1,
"immune cell infiltration":1,
"microenvironment":1,
"Fibrous dysplasia":1,
"GNAS mutation":1,
"Mc Cune Albright syndrome":1,
"biomarkers":1,
"carcinoma papillary":1,
"Papillary thyroid microcarcinoma (PTMC)":1,
"level I lymph node (level I LN)":1,
"Ablation techniques":1,
"adrenal gland neoplasms":1,
"adrenal glands":1,
"chemical ablation":1,
"cryoablation":1,
"laser-induced interstitial thermotherapy":1,
"Lymph node metastasis":1,
"Radiomics":1,
"DNA methylation":1,
"bioinformatics":1,
"Invasive ductal carcinoma":1,
"Lobular carcinoma":1,
"Molecular subtypes":1,
"SEER database":1,
"INI-1":1,
"SMARCB1":1,
"SMARCB1-deficient carcinoma of head and neck":1,
"SMARCB1-deficient sinonasal carcinoma":1,
"SWI/SNF":1,
"child":1,
"hyoid bone":1,
"thyroglossal duct cyst":1,
"flap":1,
"reconstructive surgical procedures":1,
"semi-free":1,
"transverse cervical artery":1,
"hypercholesterolemia":1,
"levothyroxine":1,
"metabolic disorders":1,
"cytochrome P450 2U1":1,
"prognostic biomarker":1,
"Central compartment neck dissection":1,
"Suprasternal space":1,
"superselective neck dissection":1,
"super‐selective neck dissection":1,
"FTC-133":1,
"caspases":1,
"crocin":1,
"Basigin":1,
"Thyroid papillary carcinoma":1,
"array comparative genomic hybridization":1,
"fine-needle aspiration":1,
"fluorescent in situ hybridization":1,
"follicular neoplasms":1,
"indeterminate cytology":1,
"GI bleeding":1,
"endoscopy":1,
"interventional radiology":1,
"Extent of thyroidectomy":1,
"Individualized decision-making":1,
"neoplasm metastasis":1,
"Pedicled rotation flap":1,
"locoregional recurrence":1,
"female patients":1,
"ovarian function":1,
"radioactive iodine therapy":1,
"sodium/iodide symporter":1,
"Breast areola approach":1,
"Natural orifice endoscopic surgery":1,
"Patient satisfaction":1,
"Safety":1,
"Surgical procedures, minimally invasive":1,
"5-Hydroxymethylcytosine":1,
"BRAF V600E":1,
"TERT promoter mutation":1,
"CCNE2":1,
"RNA-Seq":1,
"Ki-67":1,
"central lymph node metastasis":1,
"p53":1,
"ultrasonic features":1,
"Completion thyroidectomy":1,
"Complications":1,
"Nerve monitoring":1,
"Epithelial mesenchymal transition":1,
"SIX1":1,
"TGF-β/Smad2/3":1,
"integrin αvβ3":1,
"tetrac":1,
"thyroid hormones":1,
"decision-making":1,
"primary care":1,
"prostatic neoplasms":1,
"watchful waiting":1,
"RAI therapy":1,
"cancer stem cells":1,
"patient-derived tumor organoids":1,
"three-dimensional culture":1,
"treatment prediction":1,
"tumor organoids":1,
"Dose effect":1,
"U-shaped curve":1,
"Urine":1,
"Contrast":1,
"breast secondary carcinomas":1,
"clinical history":1,
"ultrasonography":1,
"Therapeutics":1,
"Thyroid cancer, medullary":1,
"clinical negligence":1,
"cytology":1,
"error":1,
"Bethesda system":1,
"cyst fluid":1,
"fine-needle aspiration cytology":1,
"reporting system":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2020年6月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
